All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Radiosensitizer Development Plan for Glioblastoma

Author(s): Hazel Grace

Glioblastoma is the most prevalent type of primary brain cancer and has a bad prognosis. New agents are desperately needed, yet nearly every Phase III study of GBM patients conducted in the last 25 years has failed to show a significant improvement in outcomes. The Glioblastoma Working Group (GBM WG) of the National Cancer Institute's Clinical Trials and Translational Research Advisory Committee (CTAC) highlighted five main areas of research in 2019 that are anticipated to be significant in the development of new GBM therapeutics. Optimizing radioresponse for GBM in situ was one of them. The inclusion of a radiosensitizer to improve the therapeutic ratio by increasing tumour sensitivity while having low to no effect on normal tissue is one such technique for increasing radiation efficacy. Although the bulk of studies involving radiosensitizers have failed in the past, they do provide valuable insight into what is needed to produce agents more quickly. Improved target selection is required for a medicine to deliver maximum benefit, and after that target has been discovered, it must be verified in preclinical research